相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Loretta Gammaitoni et al.
CLINICAL CANCER RESEARCH (2017)
Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers
Shuguang Zuo et al.
MOLECULAR IMMUNOLOGY (2017)
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
J. Gauthier et al.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2017)
5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells
Xueyang Guo et al.
SCIENTIFIC REPORTS (2017)
Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Lucia Fernandez et al.
CLINICAL CANCER RESEARCH (2017)
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review
Elisabeth Andritsch et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival
Sarah Oelsner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
Marcela V. Maus et al.
ONCOLOGIST (2016)
Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies
Elisa Cappuzzello et al.
ONCOIMMUNOLOGY (2016)
Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies
Xuequn Ren et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Targeting of IL-4 and IL-13 receptors for cancer therapy
Akiko Suzuki et al.
CYTOKINE (2015)
Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition
Angela R. Elia et al.
HUMAN GENE THERAPY (2015)
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives
Lidia Giraudo et al.
IMMUNOTHERAPY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis
Yunyuan Zhang et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)
Leonard Christopher Schmeel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
IGF1R-and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Xin Huang et al.
PLOS ONE (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas
Dario Sangiolo et al.
CANCER RESEARCH (2014)
Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Ke Pan et al.
CLINICAL CANCER RESEARCH (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
I. Pizzitola et al.
LEUKEMIA (2014)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Monica Casucci et al.
BLOOD (2013)
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
Sarah Tettamanti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
Loretta Gammaitoni et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28 OX40 Super-stimulation
Andreas A. Hombach et al.
MOLECULAR THERAPY (2013)
Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
Runmei Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF
Paul Spear et al.
JOURNAL OF IMMUNOLOGY (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Margot Zoeller
NATURE REVIEWS CANCER (2011)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial
Paola Olioso et al.
HEMATOLOGICAL ONCOLOGY (2009)
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: Are We Nearly There Yet?''
Gianpietro Dotti et al.
HUMAN GENE THERAPY (2009)
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
Ryosei Nishimura et al.
BLOOD (2008)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers
Dario Sangiolo et al.
INTERNATIONAL IMMUNOLOGY (2008)
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ activating signal
Virna Marin et al.
EXPERIMENTAL HEMATOLOGY (2007)
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
Bernard M. Tijink et al.
CLINICAL CANCER RESEARCH (2006)
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
T Leemhuis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas
S Maula et al.
BRITISH JOURNAL OF CANCER (2001)
CD44 expression in soft tissue sarcomas
N Kahara et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)
分享论文
